227 related articles for article (PubMed ID: 26624854)
1. Prediction of 1-year mortality and impact of bivalirudin therapy according to level of baseline risk: A patient-level pooled analysis from three randomized trials.
Yu J; Mehran R; Clayton T; Gibson CM; Brodie BR; Witzenbichler B; Lincoff AM; Deliargyris EN; Gersh BJ; Pocock SJ; Stone GW; Dangas GD
Catheter Cardiovasc Interv; 2016 Feb; 87(3):391-400. PubMed ID: 26624854
[TBL] [Abstract][Full Text] [Related]
2. Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry.
Hibbert B; MacDougall A; Labinaz M; O'Brien ER; So DY; Dick A; Glover C; Froeschl M; Marquis JF; Wells GA; Blondeau M; Le May MR
Circ Cardiovasc Interv; 2012 Dec; 5(6):805-12. PubMed ID: 23149331
[TBL] [Abstract][Full Text] [Related]
3. Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials.
Mehran R; Pocock S; Nikolsky E; Dangas GD; Clayton T; Claessen BE; Caixeta A; Feit F; Manoukian SV; White H; Bertrand M; Ohman EM; Parise H; Lansky AJ; Lincoff AM; Stone GW
JACC Cardiovasc Interv; 2011 Jun; 4(6):654-64. PubMed ID: 21700252
[TBL] [Abstract][Full Text] [Related]
4. Comparison of bivalirudin with heparin versus abciximab with heparin for primary percutaneous coronary intervention in "Real World" practice.
Showkathali R; Davies JR; Parker M; Taggu W; Tang KH; Clesham GJ; Gamma RA; Sayer JW; Aggarwal RK; Kelly PA
Cardiovasc Revasc Med; 2013; 14(5):289-93. PubMed ID: 23972537
[TBL] [Abstract][Full Text] [Related]
5. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW
Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052
[TBL] [Abstract][Full Text] [Related]
6. Impact of bivalirudin therapy in high-risk patients with acute myocardial infarction: 1-year results from the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) trial.
Parodi G; Antoniucci D; Nikolsky E; Witzenbichler B; Guagliumi G; Peruga JZ; Stuckey T; Dudek D; Kornowski R; Hartmann F; Lansky AJ; Mehran R; Stone GW
JACC Cardiovasc Interv; 2010 Aug; 3(8):796-802. PubMed ID: 20723849
[TBL] [Abstract][Full Text] [Related]
7. Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials.
Stone GW; Mehran R; Goldstein P; Witzenbichler B; Van't Hof A; Guagliumi G; Hamm CW; Généreux P; Clemmensen P; Pocock SJ; Gersh BJ; Bernstein D; Deliargyris EN; Steg PG
J Am Coll Cardiol; 2015 Jan; 65(1):27-38. PubMed ID: 25572507
[TBL] [Abstract][Full Text] [Related]
8. The safety and effectiveness of bivalirudin in female patients with acute myocardial infarction undergoing primary angioplasty: A subgroup analysis of the BRIGHT trial.
Liang Z; Li Y; Wang J; Wang D; Wang S; Ma L; Liu H; Yang L; Stone GW; Han Y
Catheter Cardiovasc Interv; 2016 Mar; 87 Suppl 1():608-15. PubMed ID: 26762481
[TBL] [Abstract][Full Text] [Related]
9. Effect of bivalirudin compared with unfractionated heparin plus abciximab on infarct size and myocardial recovery after primary percutaneous coronary intervention: the horizons-AMI CMRI substudy.
Wöhrle J; Merkle N; Kunze M; Cristea E; Mehran R; Rottbauer W; Stone GW
Catheter Cardiovasc Interv; 2012 Jun; 79(7):1083-9. PubMed ID: 22162175
[TBL] [Abstract][Full Text] [Related]
10. Gender-based outcomes of bivalirudin versus heparin in patients undergoing percutaneous coronary interventions: Meta-analysis of randomized controlled trials.
Mina GS; Firouzbakht T; Modi K; Dominic P
Catheter Cardiovasc Interv; 2017 Nov; 90(5):735-742. PubMed ID: 28339139
[TBL] [Abstract][Full Text] [Related]
11. Impact of antithrombotic treatment on short-term outcomes after percutaneous coronary intervention for left main disease: a pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials.
Geisler T; Müller K; Karathanos A; Bocksch W; Gawaz M; Deliargyris E; Bernstein D; Lincoff AM; Mehran R; Dangas G; Stone GW
EuroIntervention; 2014 May; 10(1):97-104. PubMed ID: 24048204
[TBL] [Abstract][Full Text] [Related]
12. Impact of Bleeding and Bivalirudin Therapy on Mortality Risk in Women Undergoing Percutaneous Coronary Intervention (from the REPLACE-2, ACUITY, and HORIZONS-AMI Trials).
Ng VG; Baumbach A; Grinfeld L; Lincoff AM; Mehran R; Stone GW; Lansky AJ
Am J Cardiol; 2016 Jan; 117(2):186-91. PubMed ID: 26704028
[TBL] [Abstract][Full Text] [Related]
13. Bivalirudin is associated with improved clinical and economic outcomes in heart failure patients undergoing percutaneous coronary intervention: Results from an observational database.
Pinto DS; Kohli P; Fan W; Kirtane AJ; Kociol RD; Meduri C; Deliargyris EN; Prats J; Reynolds MR; Stone GW; Michael Gibson C
Catheter Cardiovasc Interv; 2016 Feb; 87(3):363-73. PubMed ID: 26011467
[TBL] [Abstract][Full Text] [Related]
14. Use and Effectiveness of Bivalirudin Versus Unfractionated Heparin for Percutaneous Coronary Intervention Among Patients With ST-Segment Elevation Myocardial Infarction in the United States.
Secemsky EA; Kirtane A; Bangalore S; Jovin IS; Shah RM; Ferro EG; Wimmer NJ; Roe M; Dai D; Mauri L; Yeh RW
JACC Cardiovasc Interv; 2016 Dec; 9(23):2376-2386. PubMed ID: 27838271
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.
Rajagopal V; Lincoff AM; Cohen DJ; Gurm HS; Hu T; Desmet WJ; Kleiman NS; Bittl JA; Feit F; Topol EJ
Am Heart J; 2006 Jul; 152(1):149-54. PubMed ID: 16824845
[TBL] [Abstract][Full Text] [Related]
16. Outcome of the HORIZONS-AMI trial: bivalirudin enhances long-term survival in patients with ST-elevation myocardial infarction undergoing angioplasty.
Shah A; Feldman DN
Vasc Health Risk Manag; 2012; 8():115-23. PubMed ID: 22399856
[TBL] [Abstract][Full Text] [Related]
17. Economic impact of switching to bivalirudin for a primary percutaneous coronary intervention in a US hospital.
Olchanski N; Slawsky KA; Plent S; Kado C; Cyr PL
Hosp Pract (1995); 2010 Nov; 38(4):138-46. PubMed ID: 21068538
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction.
Nairooz R; Sardar P; Amin H; Swaminathan RV; Kim LK; Chatterjee S; Feldman DN
Am J Cardiol; 2014 Jul; 114(2):250-9. PubMed ID: 24890986
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of bivalirudin versus heparin in transradial coronary interventions.
Kheiri B; Rao SV; Osman M; Simpson TF; Barbarawi M; Zayed Y; Dhillon HN; Alkhouli M; Golwala H; Zahr F; Bhatt DL; Stone GW; Cigarroa JE
Catheter Cardiovasc Interv; 2020 Nov; 96(6):1240-1248. PubMed ID: 32091668
[TBL] [Abstract][Full Text] [Related]
20. Heparin is Not Inferior to Bivalirudin in Percutaneous Coronary Intervention-Focusing on the Effect of Glycoprotein IIb/IIIa Inhibitor Use: A Meta-Analysis.
Huang FY; Huang BT; Peng Y; Liu W; Zhao ZG; Wang PJ; Zuo ZL; Zhang C; Liao YB; Luo XL; Meng QT; Chen C; Huang KS; Chai H; Li Q; Chen M; Zhu Y
Angiology; 2015 Oct; 66(9):845-55. PubMed ID: 25635117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
